永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 01-12 16:08:28

2.790

+0.020

+0.72%

最高2.830	最低2.750	成交量34.10万
今开2.780	昨收2.770	日振幅2.89%
总市值17.24亿	流通市值17.24亿	总股本6.18亿
成交额94.53万	换手率0.06%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.79,"timestamp":1768205308562,"preClose":2.77,"halted":0,"volume":341005,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.363229,"marketStatus":"已收盘","change":0.02,"latestTime":"01-12 16:08:28","open":2.78,"high":2.83,"low":2.75,"amount":945333,"amplitude":0.028881,"askPrice":2.79,"askSize":16000,"bidPrice":2.78,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-0.397,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768267800000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.77,"openAndCloseTimeList":[[1768181400000,1768190400000],[1768194000000,1768204800000]],"volumeRatio":0.379493,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2602469615","title":"海翔药业（002099）披露签订创新药合作协议，1月12日股价上涨3.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602469615","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602469615?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:32","pubTimestamp":1768228336,"startTime":"0","endTime":"0","summary":"截至2026年1月12日收盘，海翔药业报收于7.4元，较前一交易日上涨3.06%，最新总市值为119.78亿元。近日，浙江海翔药业股份有限公司与万邦德制药集团有限公司签订《创新药合作协议》。海翔药业作为资金提供方，将投入1.5亿元人民币，获得WP205产品全球商业化收益的15%。若2027年6月30日前未能启动III期临床或获得上市许可，海翔药业有权终止协议，万邦德制药需返还全部款项并支付年化3%资金使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200037474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","002099","BK0188","BK0028","06978","BK0077","BK0192","BK1574","BK1161","BK0239"],"gpt_icon":0},{"id":"2602519380","title":"海翔药业最新公告：与万邦德制药签订创新药合作协议双方将围绕渐冻症适应症开展相关合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602519380","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602519380?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:01","pubTimestamp":1768215702,"startTime":"0","endTime":"0","summary":"海翔药业(002099.SZ)公告称，公司与万邦德制药签订《创新药合作协议》，双方将围绕渐冻症适应症开展相关合作，包括WP205产品的研发和商业化。海翔药业将提供1.5亿元资金，并享有产品商业化后15%的收益权益。该协议需经万邦德医药控股集团股份有限公司股东会审议通过后生效。存在法规政策、市场环境等风险，以及药品研发的高风险特点。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200029909.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0004","BK0050","002099","BK0077","BK0239","BK0188","BK1161","BK1574","06978","01477","BK0192","159992","BK1191","002082","BK0028"],"gpt_icon":0},{"id":"2602933518","title":"JPM 2026前瞻 | 中国创新药站上全球舞台中央","url":"https://stock-news.laohu8.com/highlight/detail?id=2602933518","media":"Ofweek光电信息网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602933518?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:58","pubTimestamp":1768208280,"startTime":"0","endTime":"0","summary":"2026年第44届摩根大通医疗健康大会将于1月12日至15日在美国旧金山举行。据披露，本届JPM的议题与参会企业或将高度集中于六大核心领域，其中生物技术板块占比最高，预计接近35%。目前，已有多家国内企业确认参会，且覆盖CXO与创新药两大核心群体。从行业趋势看，本届JPM或将进一步强化两条技术主线。进入2026年，这一趋势仍在延续。宜联生物B7H3 ADC授权给罗氏此次JPM 2026将成为国内药企集中展示核心分子竞争力、推动海外BD合作的重要窗口。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112173836a710ffe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","06978","02615","09688","BK1161","09995","BK1574","BK1583","03696","LU2328871848.SGD"],"gpt_icon":0},{"id":"2602902425","title":"中国力量在JPM大会的闪耀时刻：24家国产企业双线发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2602902425","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602902425?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:36","pubTimestamp":1768206992,"startTime":"0","endTime":"0","summary":"而今年，中国力量成为舞台上最耀眼的星光之一：24家国产医药企业集体亮相，以“主会场引领、亚太专场扩容”的双线布局，向世界展示中国医药产业的创新硬实力与全球化野心。结 语从主会场的核心发声到亚太专场的集体亮相，24家中国药企在JPM大会的舞台上，用实打实的研发成果、商业化突破与海外合作，书写着中国医药的全球化篇章。这不仅是中国力量的闪耀时刻，更预示着2026年中国创新药将在全球舞台上迎来更多突破。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112165035a710cae5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","06160","09688","BK1583","06978","BK1574","LU0588546209.SGD","LU1719994722.HKD","BK1588","LU1303224171.USD","06990","BK1161","LU2488822045.USD","BK1500","LU2328871848.SGD","LU1251922891.USD","LU1969619763.USD","09995","LU1770034418.SGD"],"gpt_icon":0},{"id":"2602659414","title":"【券商聚焦】海通国际：市场对2026年创新药产业链情绪偏积极 看好荣昌生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2602659414","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602659414?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:45","pubTimestamp":1768203955,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际研报指出，上周恒生医疗保健指数上涨10.3%，跑赢恒生指数10.7个百分点。2026年年初以来，恒生医疗保健指数涨幅为12.4%，跑赢恒生指数10.0个百分点。该机构指出，上周部分细分板块龙头显著反弹，主要归因于：一方面，前期获利了结资金影响逐步出清；另一方面，市场对2026年创新药产业链情绪偏积极，看好管线优质和推进速度快、有BD潜力、股价位置合理的板块龙头，如荣昌生物、映恩生物等。同时，受到AI主题热度高涨影响，AI医疗概念走强，高增速、业绩兑现度高的主题标的医脉通、平安好医生涨幅明显。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/N2I4ZDVmMTM1NjM3MTU3MjA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1615","BK0239","06978","LU1969619763.USD","LU1064131003.USD","LU1046422090.SGD","BK1587","LU1235295612.USD","BK1571","BK1617","BK1583","09995","LU2543165471.USD","HK0000252160.HKD","01833","LU2148510915.USD","09606","159992","02192","BK1142","LU2488822045.USD","BK1515","LU0049112450.USD","BK1189","LU1064130708.USD","BK1161","HK0000252152.HKD","BK1219","HK0000500386.USD","LU2328871848.SGD","BK1247","688331"],"gpt_icon":0},{"id":"2602560433","title":"创新药板块的强心剂! Piper Sandler押注“基因沉默”领军者Arrowhead(ARWR.US) 预言股价将狂飙55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602560433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602560433?lang=zh_cn&edition=full","pubTime":"2026-01-12 12:01","pubTimestamp":1768190468,"startTime":"0","endTime":"0","summary":"Piper Sandler予以Arrowhead Pharmaceuticals的100美元这一12个月内无比强劲的看涨目标价位，堪称对于当前处于回调阶段的全球创新药领域的一针重磅强心剂。今年以来Arrowhead Pharmaceuticals股价表现不佳，年内迄今跌近3%，大幅跑输标普500指数。这也是Arrowhead的第一款获得FDA批准上市的药物，标志着其从临床阶段向商业化阶段的转变。该公司推出了用于FCS的Redemplo，来自Piper Sandler的分析师Edward Tenthoff指出。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK4588","BK4139","ARWR","159992","06978","BK4585"],"gpt_icon":0},{"id":"2602584391","title":"公募开年力推医药基金！创新药迎“赚美元”新周期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602584391","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602584391?lang=zh_cn&edition=full","pubTime":"2026-01-10 17:09","pubTimestamp":1768036154,"startTime":"0","endTime":"0","summary":"在创新药定价逻辑跨进“赚美元”阶段之际，各大公募2026开年火速投放医药新基金。随着中国创新药行业逐步迈入“赚美元”的全球化变现周期，公募基金迅速推出各类医药新品。开年不足一周，创新药赛道便迎来了新产品发行的接力潮。基金料创新药拥抱全球化定价创新药赛道正迈向“赚美元”阶段，这一根本性转变，成为众多基金经理看好其估值重构的核心引擎。届时，中国创新药首批海外三期临床结果将陆续读出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110170933a70a63ad&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260110170933a70a63ad&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","02228","BK1161","BK1141","BK1574","BK1617"],"gpt_icon":0},{"id":"2602458720","title":"天风·医药 | 炎症性肠病——市场空间大，研发路径愈发清晰，中国创新药公司有望深度参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2602458720","media":"天风研究","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602458720?lang=zh_cn&edition=full","pubTime":"2026-01-10 17:00","pubTimestamp":1768035600,"startTime":"0","endTime":"0","summary":"IBD的患者人群庞大，且存在未满足的治疗需求，2024年药物销售规模约240亿美金。现有治疗药物中，乌帕替尼综合疗效最优，但存在安全性问题。中国创新药公司有望深度参与IBD大赛道。2024年IBD患者数量接近91万人，并预计2025年患者数将达150万，由少见病走向常见病。中国创新药公司有望深度参与IBD大赛道在前沿靶点上，中国药企在TL1A方向储备较多，有超20款药物在研，覆盖单抗与双抗等形态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["research"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzAwMzIzNzcwMg==&mid=2649150073&idx=3&sn=33ddf17fa4338eb2ef1ebec896a293b3&chksm=825e9afb02658828265e79311851b2ded48fd57cb041b4d431b7d1514651f9ac3bc8e49526b2&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06978","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2602818945","title":"一图速览 | 当前为什么看好创新药？","url":"https://stock-news.laohu8.com/highlight/detail?id=2602818945","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602818945?lang=zh_cn&edition=full","pubTime":"2026-01-10 11:28","pubTimestamp":1768015680,"startTime":"0","endTime":"0","summary":"相关研报：华泰 | 医药：看好创新药流动性修复叠加多重催化","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649840617&idx=3&sn=f34c64b257b171a43bcdf615bc43d4b9&chksm=893fdacb440c67cf65fb0d03148258317031c229d87eaca19f741a231492cee96307980b7089&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06978","BK1161","BK1574","159992"],"gpt_icon":0},{"id":"2602754883","title":"海南海药最新公告：创新药派恩加滨片Ⅱa期临床试验研究结果发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754883","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602754883?lang=zh_cn&edition=full","pubTime":"2026-01-09 20:50","pubTimestamp":1767963010,"startTime":"0","endTime":"0","summary":"海南海药(000566.SZ)公告称，公司全资子公司海口市制药厂有限公司与中国科学院上海药物研究所联合研究开发的创新药派恩加滨项目，于近日完成了Ⅱa期临床试验，初步研究结果显示达到主要及次要临床终点。派恩加滨属于化药1类，为新型抗癫痫药物，新一代KCNQ钾通道激动剂，目前全球尚无上市品种，本品可用于难治性癫痫的治疗。本次仅为派恩加滨完成中国Ⅱa期临床试验结果分析，后续尚需完成Ⅱb期及Ⅲ期临床试验，并经国家药监局批准后方可上市。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900038074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","000566","BK0146","06978","BK0060","BK0070","BK1574","BK0239","BK1161","BK0188"],"gpt_icon":0},{"id":"2602327673","title":"信诺维科创板IPO已问询 已开发10款主要在研创新药管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2602327673","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602327673?lang=zh_cn&edition=full","pubTime":"2026-01-09 18:56","pubTimestamp":1767956161,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月9日，苏州信诺维医药科技股份有限公司申请上交所科创板上市审核状态变更为“已问询”，国泰海通证券为其保荐机构，拟募资29.40亿元。公司已形成“1+3+N”的创新药管线2梯队，并通过全球BD3授权或转让初步实现了以研养研。公司在研管线获得的监管促进资格数量在国内药企中名列前茅。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1574","159982","06978","159992"],"gpt_icon":0},{"id":"2602328935","title":"万邦德(002082.SZ)：阿尔茨海默病项目入选创新药物研发国家科技重大专项","url":"https://stock-news.laohu8.com/highlight/detail?id=2602328935","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602328935?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:50","pubTimestamp":1767945036,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万邦德(002082.SZ)公告，公司全资子公司万邦德制药集团有限公司(“万邦德制药”)阿尔茨海默病项目入选了由中国科学院上海药物研究所牵头的创新药物研发国家科技重大专项项目，已收到国家卫生健康委员会中国生物技术发展中心下发的立项批复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002082","BK0239","159992","BK1161","BK0050","BK0004","BK1574","BK0028","06978"],"gpt_icon":0},{"id":"2602532906","title":"恒瑞医药：创新药销售引领业绩增长，多举措促公司持续发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2602532906","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602532906?lang=zh_cn&edition=full","pubTime":"2026-01-09 15:05","pubTimestamp":1767942300,"startTime":"0","endTime":"0","summary":"2025年上半年，公司创新药销售及许可收入95.61 亿元，占公司营业收入比重60.66%。此外，公司自2023年以来达成12笔创新成果对外授权，潜在总交易额超270亿美元。同时，也将着力于产品结构的优化提升，通过产品创新升级和多元化产品管线的拓展推动公司的持续发展，促进公司业绩可持续增长，以更好的发展回馈股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161527a7066326&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109161527a7066326&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","BK1574","01276","LU0359201612.USD","LU2543165471.USD","06978","BK1161","BK1191","LU0359202008.SGD"],"gpt_icon":0},{"id":"2602034264","title":"创新药概念震荡走强 前沿生物等多股涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602034264","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602034264?lang=zh_cn&edition=full","pubTime":"2026-01-09 13:24","pubTimestamp":1767936240,"startTime":"0","endTime":"0","summary":"每经AI快讯，1月9日，午后创新药概念震荡走强，维康药业（维权）、上海谊众、前沿生物涨超10%，联环药业逼近涨停，泓博医药、智翔金泰、键凯科技跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-09/doc-inhfssrv0603485.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-09/doc-inhfssrv0603485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688221","159992","BK1574","BK0239","BK1161","06978"],"gpt_icon":0},{"id":"2602884312","title":"【券商聚焦】华泰证券：开年以来的流动性修复有望提振创新药板块β","url":"https://stock-news.laohu8.com/highlight/detail?id=2602884312","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602884312?lang=zh_cn&edition=full","pubTime":"2026-01-09 08:58","pubTimestamp":1767920334,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券表示，自9月港股创新药年内新高以来，港股创新药指数截止到年底回调24%，而同期美股生物科技指数XBI涨幅29%，NBI指数涨幅18%。XBI自4月底部反弹超过100%，大型MNC普遍自底部反弹30~50%，礼来市值首次突破万亿美金。步入新的一年，港股创新药迎来开门红。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，该机构认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1972900","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","BK1141","IE00B5MMRT66.SGD","01877","LU0417516571.SGD","LU1226287792.SGD","LU0588546209.SGD","LU1979443071.USD","LU1934453819.USD","06160","02616","02142","09688","LU2097828805.USD","LU3063872942.SGD","LU1960683339.HKD","LU0516423174.USD","06185","LU0067412154.USD","LU0315179316.USD","LU0502904849.HKD","LU1064131003.USD","02269","LU1807302812.USD","LU0516422952.EUR","159992","01177","BK1589","01093","06978","IE0008369823.USD","LU0561508036.HKD","BK0183","BK0012","LU2476274720.SGD","LU0307460666.USD","LU1328277881.USD","LU0501845795.SGD","LU1993786604.SGD","LU2097828474.EUR","LU0039217434.USD","LU0516422440.USD","BK1500","09995","LU1152091168.USD","LU2148510915.USD","LU1242518857.USD","01801","LU0043850808.USD","601688"],"gpt_icon":0},{"id":"2602349302","title":"华泰 | 医药：看好创新药流动性修复叠加多重催化","url":"https://stock-news.laohu8.com/highlight/detail?id=2602349302","media":"华泰睿思","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602349302?lang=zh_cn&edition=full","pubTime":"2026-01-09 07:44","pubTimestamp":1767915840,"startTime":"0","endTime":"0","summary":"步入新的一年，港股创新药迎来开门红。回顾2025年中美创新药走势，我们认为港股创新药估值较全球同类产品仍有绝对吸引力，流动性折价是11-12月创新药下跌的主因。随着流动性修复及对外BD持续，以及JPM峰会、年报周期的BD旺季和数据披露高峰的到来，我们认为开年以来的流动性修复有望提振创新药板块β，上涨趋势有望持续。如因侵权行为给华泰证券造成任何直接或间接的损失，华泰证券保留追究一切法律责任的权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5NDI5MDQwMg==&mid=2649840507&idx=3&sn=9a91fa71742e3cf064dae602926fa680&chksm=89efe1dd2d78071420c93455f3ffd5ab868e110a2bb71b5c598df6e02a3e8ee9a354c39cc920&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159992","BK1515","06978","BK1574","09939","BK1161","159938"],"gpt_icon":0},{"id":"2602319923","title":"审评审批新政开路，加速引进临床急需境外已上市药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2602319923","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602319923?lang=zh_cn&edition=full","pubTime":"2026-01-09 07:00","pubTimestamp":1767913200,"startTime":"0","endTime":"0","summary":"国家药监局发布的新政，正在打开一扇让全球创新药物更快进入中国的大门，从罕见病到慢性病，数千种境外已上市药品的准入时间表将被改写。其中明确，鼓励临床急需境外已上市的原研药及仿制药在境内申报，对于符合要求的可纳入优先审评审批范围。　　另外，对于临床急需境外已上市境内未上市的罕见病药品，鼓励申请人采取前置检验方式申请注册检验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-01-09/doc-inhfrzuc0782729.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-01-09/doc-inhfrzuc0782729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","BK1574","06978"],"gpt_icon":0},{"id":"2602373081","title":"医药生物行业炎症性肠病：市场空间大 研发路径愈发清晰 中国创新药公司有望深度参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2602373081","media":"天风证券","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602373081?lang=zh_cn&edition=full","pubTime":"2026-01-09 00:00","pubTimestamp":1767888000,"startTime":"0","endTime":"0","summary":"2024 年IBD 患者数量接近91 万人，并预计2025 年患者数将达150 万，由少见病走向常见病。根据Abivax估算，2024 年至2030 年IBD 药物市场有望从237 亿美元增至308 亿美元，其中UC 增速更快。中国创新药公司有望深度参与IBD 大赛道在前沿靶点上，中国药企在TL1A 方向储备较多，有超20 款药物在研，覆盖单抗与双抗等形态。此外，辰欣药业的WXSH0176 已开展UC 的临床试验，未来可期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109152515a4af33a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109152515a4af33a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","09969","BK1161"],"gpt_icon":0},{"id":"2601363983","title":"绿叶制药(02186)：1类创新药若欣林®用于治疗广泛性焦虑障碍的新适应症中国上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363983","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601363983?lang=zh_cn&edition=full","pubTime":"2026-01-08 19:03","pubTimestamp":1767870230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，绿叶制药 发布公告，中国国家药品监督管理局药品审评中心已正式受理本集团1类创新药若欣林的新适应症上市申请，拟用于治疗广泛性焦虑障碍。这是该产品自2022年11月获批上市用于治疗抑郁症后的又一里程碑。该研究纳入555例患者，以汉密尔顿焦虑量表总分较基线变化为主要终点，评估若欣林治疗广泛性焦虑障碍的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1390499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1161","BK1191","BK1606","159992","BK1574","06978","02186"],"gpt_icon":0},{"id":"2601949398","title":"创新药“华山奖”企业奖36家入围名单公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2601949398","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601949398?lang=zh_cn&edition=full","pubTime":"2026-01-08 18:19","pubTimestamp":1767867540,"startTime":"0","endTime":"0","summary":"“医学界”与“同写意”共同发起的创新药“华山奖”企业奖入围名单公布，共36家企业入围。奖项旨在发现中国创新药价值医疗标杆，通过量化指标评选产生。奖项分三类：最佳领导型创新医药企业奖，要求企业具有卓越综合实力、深远行业影响力等，年药品销售收入在100亿元以上，百济神州、阿斯利康等12家企业入围；最佳成长型创新医药企业奖，要求企业展现出卓越成长潜力，年药品销售收入处于10亿-100亿元之间，信达生物、传奇生物等12家企业入围；最佳潜力型创新医药企业奖，要求企业展现出卓越创新能力，年药品销售收入在10亿元以下或未有商业化产品，和铂医药、科伦博泰生等2家企业（名单未完全列举）入围。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108184317a4abbfff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260108184317a4abbfff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","06978","BK1574","06160","BK1161","02142"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0315},{"period":"1month","weight":-0.0315},{"period":"3month","weight":-0.4069},{"period":"6month","weight":-0.2284},{"period":"1year","weight":0.1888},{"period":"ytd","weight":-0.0546}],"compareEarnings":[{"period":"1week","weight":-0.0041},{"period":"1month","weight":0.0271},{"period":"3month","weight":-0.0022},{"period":"6month","weight":0.0867},{"period":"1year","weight":0.3633},{"period":"ytd","weight":0.0235}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.063839},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}